Alternative Data for Iovance Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 11 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 14,000 | Sign up | Sign up | Sign up |
| Employee Rating | 52 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,749 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,704 | Sign up | Sign up | Sign up |
| X Followers | 2,155 | Sign up | Sign up | Sign up |
| X Mentions | 69 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 18 | Sign up | Sign up | Sign up |
| Linkedin Employees | 920 | Sign up | Sign up | Sign up |
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
| Price | $3.96 |
| Target Price | Sign up |
| Volume | 27,551,172 |
| Market Cap | $1.68B |
| Year Range | $1.7 - $5.41 |
| Dividend Yield | 0% |
| Analyst Rating | 90% buy |
| Industry | Biotechnology |
In the news
 |
Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi MomentumMarch 6 - Ibtimes.com.au |
UBS Raises PT on Iovance Biotherapeutics (IOVA)March 6 - Yahoo Entertainment |
|
Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)February 23 - SeekingAlpha |
|
 |
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical ProgressFebruary 23 - ChartMill |
 |
Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call TranscriptFebruary 23 - SeekingAlpha |
Iovance Biotherapeutics shares are trading higher after the company reported better-than-expected Q4 sales results. Also, the company announced early data form its pilot clinical trial in patients with advanced UPS or dedifferentiated liposarcoma.February 23 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 67M | 1.4M | 66M | -91M | -85M | -0.250 |
| Q2 '25 | 60M | 57M | 3.3M | -112M | -102M | -0.330 |
| Q1 '25 | 49M | 50M | -420,000 | -116M | -107M | -0.360 |
| Q4 '24 | 74M | 46M | 28M | -79M | -75M | -0.260 |
| Q3 '24 | 59M | 40M | 19M | -84M | -78M | -0.280 |
Insider Transactions View All
| Kirby Daniel Gordon filed to buy 30,000 shares at $1.8. June 6 '25 |
| Puri Raj K. filed to buy 206,852 shares at $1.7. May 27 '25 |
| Vogt Frederick G filed to buy 374,646 shares at $1.7. May 16 '25 |
| Maynard Ryan D filed to sell 7,500 shares at $10.1. November 14 '24 |
| Dukes Iain D. filed to buy 54,000 shares at $9.2. February 20 '24 |
Similar companies
Read more about Iovance Biotherapeutics (IOVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Iovance Biotherapeutics
The Market Cap of Iovance Biotherapeutics is $1.68B.
Currently, the price of one share of Iovance Biotherapeutics stock is $3.96.
The IOVA stock price chart above provides a comprehensive visual representation of Iovance Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Iovance Biotherapeutics shares. Our platform offers an up-to-date IOVA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Iovance Biotherapeutics (IOVA) does not offer dividends to its shareholders. Investors interested in Iovance Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Iovance Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
